Form 4: Heron Therapeutics CEO Craig Collard Reports Stock Transactions
SEC Form 4
CEO Craig Collard reports the vesting of restricted stock units into Heron Therapeutics common stock.
Summary
- On April 19, 2025, Craig Collard, CEO of Heron Therapeutics, reported a transaction involving the vesting of 13,796 restricted stock units into common stock.
- Following the transaction, Collard directly owns 391,163 shares of Heron Therapeutics common stock.
- He also directly owns 151,766 restricted stock units.
- The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024).
Sentiment
Score: 5
Explanation: This is a routine disclosure of stock transactions by a company executive, and does not inherently indicate positive or negative sentiment.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders.
Stakeholder Impact
- The transaction increases the number of outstanding shares, which could have a minor dilutive effect on existing shareholders.
Key Dates
| Date | Description |
|---|---|
| 01/19/2024 | Date of grant for restricted stock units, which vest in 16 equal quarterly installments beginning one quarter after this date. |
| 04/19/2025 | Date of transaction: vesting of 13,796 restricted stock units into common stock. |
| 04/22/2025 | Date of signature on the Form 4 filing. |
Keywords
Heron Therapeutics, Craig Collard, stock, restricted stock units, HRTX, CEO, Form 4, vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.